腺相关病毒载体(血清型2)-神经生长因子治疗阿尔茨海默病患者:一项随机临床试验
这项多中心2期随机临床试验将49例轻中度阿尔茨海默病(AD)患者按1:1随机分配接受AAV2-NGF立体定向脑内注射或假手术,主要终点为24个月时ADAS-cog评分变化。结果显示AAV2-NGF安全且耐受良好,但治疗组与安慰剂组在主要结局上无显著差异(平均[SD]评分14.52[4.66] vs 9.11[4.65],P=0.17)。作者认为该研究证明了假手术对照的立体定向基因递送研究的可行性,但AAV2-NGF未影响临床结局或所选AD生物标志物,需要病理学确认基因靶向的准确性。
要点
- AAV2-NGF立体定向脑内注射在24个月内安全且耐受良好。
- 主要终点ADAS-cog评分治疗组与安慰剂组无显著差异(P=0.17)。
- 作者认为该研究证明了假手术对照的立体定向基因递送研究的可行性,但需要病理学确认基因靶向的准确性。
核心结论
- AAV2-NGF递送耐受良好,但未影响临床结局或所选AD生物标志物。
- 该多中心随机临床试验证明了在AD患者中进行假手术对照的立体定向基因递送研究的可行性。
- 需要病理学确认基因靶向的准确性。
研究设计与样本
- 多中心2期随机临床试验,49例轻中度AD患者按1:1随机分配接受AAV2-NGF立体定向脑内注射或假手术。
- 参与者于2009年11月至2012年12月入组,分析于2015年2月开始,研究在美国10个学术医学中心进行。
- 纳入标准为轻中度AD所致痴呆且年龄55至80岁;共39例未通过筛选,最常见原因为简易精神状态检查评分低于 cutoff。
- 分析为意向性治疗。
主要发现
- 49例参与者中21例(43%)为女性,42例(86%)自认为白人,平均(SD)年龄68(6.4)岁。
- AAV2-NGF在24个月内安全且耐受良好。
- 主要结局指标ADAS-cog评分治疗组与安慰剂组无显著差异(平均[SD]评分14.52[4.66] vs 9.11[4.65],P=0.17)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要病理学确认基因靶向的准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Nerve growth factor (NGF) is an endogenous neurotrophic factor that prevents the death and augments the functional state of cholinergic neurons of the basal forebrain, a cell population that undergoes extensive degeneration in Alzheimer disease (AD). OBJECTIVE: To determine whether stereotactically guided intracerebral injections of adeno-associated viral vector (serotype 2)-nerve growth factor (AAV2-NGF) are well tolerated and exhibit preliminary evidence of impact on cognitive decline in mild to moderate AD-associated dementia. DESIGN, SETTING, AND PARTICIPANTS: In a multicenter phase 2 trial, 49 participants with mild to moderate AD were randomly assigned in a 1:1 ratio to receive stereotactically guided intracerebral injections of AAV2-NGF or sham surgery. Participants were enrolled between November 2009 and December 2012. Analyses began in February 2015. The study was conducted at 10 US academic medical centers. Eligibility required a diagnosis of mild to moderate dementia due to AD and individuals aged 55 to 80 years. A total of 39 participants did not pass screening; the most common reason was Mini-Mental State Examination scores below cutoff. Analyses were intention-to-treat. INTERVENTIONS: Stereotactically guided intracerebral injections of AAV2-NGF into the nucleus basalis of Meynert of each hemisphere or sham surgery. MAIN OUTCOMES AND MEASURES: Change from baseline on the Alzheimer's Disease Assessment Scale-cognitive subscale at month 24. RESULTS: Among 49 participants, 21 (43%) were women, 42 (86%) self-identified as white, and the mean (SD) age was 68 (6.4) years. AAV2-NGF was safe and well-tolerated through 24 months. No significant difference was noted between the treatment group and placebo on the primary outcome measure, the Alzheimer's Disease Assessment Scale-cognitive subscale (mean [SD] score, 14.52 [4.66] vs 9.11 [4.65], P = .17). CONCLUSIONS AND RELEVANCE: This multicenter randomized clinical trial demonstrated the feasibility of sham-surgery-controlled stereotactic gene delivery studies in patients with AD. AAV2-NGF delivery was well-tolerated but did not affect clinical outcomes or selected AD biomarkers. Pathological confirmation of accurate gene targeting is needed. TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT00876863.
引用
- Rafii MS, Tuszynski MH, Thomas RG, et al. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29582053. doi:10.1001/jamaneurol.2018.0233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。